Seasonal Vaccine Availability
RSV Season
Beyfortus (nirsevimab-alip) may be administered from October through the end of March in most of the continental United States. Nirsevimab is available for ordering for the upcoming RSV season. On June 9th, the FDA approved Merck’s ENFLONSIA™ (clesrovimab-cfor) for prevention of Respiratory Syncytial Virus (RSV). Providers will be notified when it is available for VFC-eligible children.
Influenza Season
Some formulations of Influenza vaccine are now available. During its June meeting, the ACIP recommended use of thimerosal-free single-dose formulations for this year’s seasonal flu vaccines for children 18 years and younger, pregnant women, and adults. Providers who pre-booked formulations with thimerosal have been informed of preservative-free substitutions.
COVID-19 Season
FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) met on May 22, 2025, to discuss and make recommendations on the selection of the 2025-2026 formula for COVID-19 vaccines. The committee unanimously voted to recommend a monovalent JN.1-lineage vaccine composition, with a preference for the LP.8.1 variant. COVID-19 vaccine is expected to be available from three vaccine manufacturers, Moderna (Spikevax), Sanofi (Nuvaxovid), and Pfizer (BioNTech and Comirnaty) in the fall of 2025 upon licensure of the 2025-26 vaccines.
|
